ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT)
CUSIP: H0036K147
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Shares, par value CHF 0.08 per share
- Shares outstanding
- 128,210,515
- Total 13F shares
- 67,952,003
- Share change
- +13,200,122
- Total reported value
- $182,114,158
- Put/Call ratio
- 111%
- Price per share
- $2.68
- Number of holders
- 84
- Value change
- +$35,606,077
- Number of buys
- 30
- Number of sells
- 49
Quarterly Holders Quick Answers
What is CUSIP H0036K147?
CUSIP H0036K147 identifies ADCT - ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP H0036K147:
Top shareholders of ADCT - ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Redmile Group, LLC |
13F
|
Company |
12%
|
15,666,731
|
$22,090,091 | — | 31 Mar 2025 | |
| HPWH TH AG |
13D/G
|
Dr. Hans-Peter Wild |
9.6%
|
9,788,944
|
$14,291,858 | $0 | 15 May 2025 | |
| Hans Peter Wild |
3/4/5
|
10%+ Owner |
7.6%
|
9,788,944
|
$14,291,858 | — | 15 May 2025 | |
| Prosight Management, LP |
13F
|
Company |
7.4%
|
9,543,004
|
$13,455,636 | — | 31 Mar 2025 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
4.7%
|
5,968,451
|
$8,415,516 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13D/G
13F
|
Company |
5%
|
4,913,153
|
$7,173,203 | -$144,108 | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
2.4%
|
3,019,585
|
$4,257,615 | — | 31 Mar 2025 | |
| PLATINUM INVESTMENT MANAGEMENT LTD |
13F
|
Company |
1.6%
|
2,038,087
|
$2,873,703 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
1.4%
|
1,801,154
|
$2,539,627 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.2%
|
1,583,112
|
$2,232,188 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.94%
|
1,211,346
|
$1,707,998 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.76%
|
969,747
|
$1,367,342 | — | 31 Mar 2025 | |
| Vantage Consulting Group Inc |
13F
|
Company |
0.66%
|
850,737
|
$1,199,539 | — | 31 Mar 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.64%
|
815,531
|
$1,149,899 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0.6%
|
767,064
|
$1,081,560 | — | 31 Mar 2025 | |
| Blue Owl Capital Holdings LP |
13F
|
Company |
0.57%
|
733,568
|
$1,034,331 | — | 31 Mar 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.54%
|
692,078
|
$975,830 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.51%
|
652,007
|
$919,329 | — | 31 Mar 2025 | |
| Peter Hug |
3/4/5
|
Director |
0.17%
|
220,500
|
$789,390 | — | 13 Jun 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.39%
|
496,144
|
$699,563 | — | 31 Mar 2025 | |
| Viviane Monges |
3/4/5
|
Director |
0.11%
|
144,043
|
$515,673 | — | 13 Jun 2025 | |
| Victor Sandor |
3/4/5
|
Director |
0.08%
|
108,286
|
$387,663 | — | 13 Jun 2025 | |
| Jean-Pierre Bizzari |
3/4/5
|
Director |
0.08%
|
106,902
|
$382,709 | — | 13 Jun 2025 | |
| Ron Squarer |
3/4/5
|
Director |
0.07%
|
93,627
|
$335,184 | — | 13 Jun 2025 | |
| DAFNA Capital Management LLC |
13F
|
Company |
0.17%
|
224,081
|
$315,954 | — | 31 Mar 2025 | |
| Robert Azelby |
3/4/5
|
Director |
0.06%
|
80,405
|
$287,849 | — | 13 Jun 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.16%
|
201,170
|
$283,651 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.15%
|
194,258
|
$273,904 | — | 31 Mar 2025 | |
| Thomas Pfisterer |
3/4/5
|
Other* |
0.14%
|
173,899
|
$253,892 | — | 15 May 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.13%
|
164,817
|
$232,392 | — | 31 Mar 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.12%
|
159,466
|
$224,847 | — | 31 Mar 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.12%
|
152,047
|
$214,386 | — | 31 Mar 2025 | |
| FMR LLC |
13F
|
Company |
0.11%
|
136,416
|
$192,346 | — | 31 Mar 2025 | |
| Invesco Ltd. |
13F
|
Company |
0.1%
|
132,704
|
$187,113 | — | 31 Mar 2025 | |
| Florida Trust Wealth Management Co |
13F
|
Company |
0.09%
|
113,000
|
$159,330 | — | 31 Mar 2025 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.09%
|
111,629
|
$157,388 | — | 31 Mar 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.08%
|
103,780
|
$146,330 | — | 31 Mar 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.08%
|
101,034
|
$142,458 | — | 31 Mar 2025 | |
| Wilmington Savings Fund Society, FSB |
13F
|
Company |
0.08%
|
100,000
|
$141,000 | — | 31 Mar 2025 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.07%
|
91,873
|
$129,541 | — | 31 Mar 2025 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0.05%
|
67,777
|
$95,566 | — | 31 Mar 2025 | |
| INTECH INVESTMENT MANAGEMENT LLC |
13F
|
Company |
0.05%
|
62,872
|
$88,650 | — | 31 Mar 2025 | |
| CITIGROUP INC |
13F
|
Company |
0.04%
|
57,646
|
$81,281 | — | 31 Mar 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.04%
|
56,062
|
$79,047 | — | 31 Mar 2025 | |
| Magnetar Financial LLC |
13F
|
Company |
0.04%
|
55,762
|
$78,624 | — | 31 Mar 2025 | |
| PANAGORA ASSET MANAGEMENT INC |
13F
|
Company |
0.04%
|
54,186
|
$76,402 | — | 31 Mar 2025 | |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. |
13F
|
Company |
0.04%
|
48,563
|
$68,474 | — | 31 Mar 2025 | |
| MetLife Investment Management, LLC |
13F
|
Company |
0.04%
|
45,487
|
$64,137 | — | 31 Mar 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.03%
|
44,686
|
$63,007 | — | 31 Mar 2025 | |
| Corebridge Financial, Inc. |
13F
|
Company |
0.03%
|
39,838
|
$56,172 | — | 31 Mar 2025 |
Institutional Holders of ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) as of Q2 2025
As of 30 Jun 2025,
ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) was held by
84 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
67,952,003 shares.
The largest 10 holders included
Redmile Group, LLC, Prosight Management, LP, Point72 Asset Management, L.P., ORBIMED ADVISORS LLC, BlackRock, Inc., MORGAN STANLEY, HEIGHTS CAPITAL MANAGEMENT, INC, Nantahala Capital Management, LLC, BANK OF AMERICA CORP /DE/, and GOLDMAN SACHS GROUP INC.
This page lists
84
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
82
Q2 2025 holders
84
Holder diff
2
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.